Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy (RER-CRT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Larisa Tereshchenko, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01924221
First received: August 14, 2013
Last updated: September 1, 2015
Last verified: September 2015

August 14, 2013
September 1, 2015
December 2011
January 2021   (final data collection date for primary outcome measure)
Sustained ventricular tachyarrhythmias [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01924221 on ClinicalTrials.gov Archive Site
Heart Failure Hospitalizations [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Same as current
All-cause mortality [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Same as current
 
Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy
Study of Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy
Cardiac resynchronization therapy with pacemaker alone, or in combination with a cardioverter-defibrillator, prolongs life and decreases risk of heart failure exacerbation in patients with low ejection fraction and wide QRS. Some patients achieve decrease in QRS duration 6 months after cardiac resynchronization therapy. Such fenomenon is called reverse electrical remodeling of native conduction. Retrospective analysis showed that reverse electrical remodeling of the native conduction after at least 6 months of CRT is associated with decreased rate of ventricular arrhythmias and better survival. This study is designed to study reverse electrical remodeling prospectively.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Heart Failure Patients with currently approved indications for implantation of cardiac resynchronization therapy defibrillator
  • Heart Failure.
  • An Approved Indication Per ACC/AHA/HRS Guidelines for Implantation of a Cardiac Resynchronization Therapy Defibrillator
Other: this is an observational study. No intervention
CRT
Patients with implanted cardiac resynchronization therapy defibrillator
Intervention: Other: this is an observational study. No intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
70
January 2021
January 2021   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • an approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D

Exclusion Criteria:

  • age < 18 y
  • pregnancy or planned pregnancy
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01924221
RER CRT, NA_00065477
No
Not Provided
Not Provided
Larisa Tereshchenko, Johns Hopkins University
Johns Hopkins University
Not Provided
Principal Investigator: Larisa Tereshchenko, MD, PhD Johns Hopkins University
Johns Hopkins University
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP